Our experimental findings showed that in the phase of inflammation regression, HRP inhibited NF-κB by upregulating PKA activated by cAMP and inhibited TNF-α and IL-1β, which resulted in liver inflammation regression and restoration of damaged CYP2D6 and liver function. This evidence concerns the gene NFKB1 and Hepatitis.